This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

SANOFI: Solid Sales And Business EPS(1) Growth At CER In Q2 2014

PARIS, July 31, 2014 (GLOBE NEWSWIRE) --

Solid sales and Business EPS (1) growth at CER in Q2 2014

Growth trajectory continues in the second quarter Group sales(2) up 6.4%(3) to €8,075 million driven by Genzyme (+29.1%) and Diabetes (+16.2%). Growth platforms(4) up 14.5%(3) to €6,163 million, representing 76.3% of total sales. Business net income(1) increased 13.0% at CER to €1,537 million, (+3.9% on a reported basis). Business EPS(1) grew 13.4% at CER to €1.17. Free Cash Flow(5) increased 33.1% to €2,390 million in H1 2014. Strong growth in Emerging Markets and executing on new launches Emerging Markets(6) sales grew 16.5%(3) to €2,855 million representing 35.4% of total Group sales. Merial grew 6.2% driven by a strong NexGard(TM) launch. Successful Nasacort® OTC launch in the U.S. contributed to CHC sales growth of 9.2%(7). Significant advances achieved in the R&D pipeline Positive results from nine Phase III ODYSSEY studies with alirocumab for hypercholesterolemia. Positive Phase III results for Toujeo® presented at ADA; filings submitted in the U.S., EU and Japan. Strong Phase II data sets with dupilumab in atopic dermatitis; Phase III expected to begin later this year. New detailed data from a positive Phase III trial with sarilumab in rheumatoid arthritis presented at EULAR. Lemtrada(TM) resubmission in multiple sclerosis accepted for review by the FDA. Financial guidance for 2014 adjusted Given our financial performance in H1 2014 and despite increasing U.S. competitive pressure at the payor level, 2014 business EPS is expected to be between 6% to 8% higher than 2013 at CER(1), barring major unforeseen adverse events.
Sanofi Chief Executive Officer, Christopher A. Viehbacher commented: "Our solid second quarter performance reflects consistent execution of our growth strategy and allows us to slightly adjust upwards our 2014 financial guidance. This quarter, growth platforms represented more than 75% of our sales. Based on the solid momentum in our late stage pipeline, we are actively preparing for a wave of new product launches that will further redefine Sanofi as a biopharmaceutical leader."

(1) See Appendix 10 for definitions of financial indicators; (2) Growth in net sales is expressed at constant exchange rates (CER) unless otherwise indicated (see Appendix 10 for a definition); (3) Excluding generics in Brazil, Group sales grew 3.9%, growth platforms grew 10.7% and Emerging Markets grew 8.6%; (4) See page 2; (5) Free Cash Flow after capital expenditures; (6) See definition on page 10; (7) Including the change of category, sales of CHC grew 20.2%.

Investor Relations: (+) 33 1 53 77 45 45 - E-mail : IR@sanofi.com     -     Media Relations: (+) 33 1 53 77 46 46 - E-mail : MR@sanofi.com        Web site : www.sanofi.com   Mobile app : SANOFI IR available on the App Store and Google Play

2014 second-quarter and first-half key figures

  Q2 2014 Change (reported) Change (CER) H1 2014 Change (reported) Change (CER)
Net sales €8,075m +0.9% +6.4% €15,917m -0.9% +4.9%
Business net income (1) €1,537m +3.9% +13.0% €3,084m +0.2% +9.2%
Business EPS (1) €1.17 +4.5% +13.4% €2.34 +0.9% +9.9%

In order to facilitate an understanding of our operational performance, Sanofi comments on the business net income statement. Business net income (1) is a non-GAAP financial measure. The consolidated income statement for H1 2014 is provided in Appendix 4 and a reconciliation of business net income to consolidated net income in Appendix 3. Consolidated net income for H1 2014 was €1,861 million compared to €1,437 million for H1 2013. Consolidated EPS for H1 2014 was €1.41 versus €1.09 for H1 2013.

2014 second-quarter and first-half sales

Unless otherwise indicated, all sales growth figures in this press release are stated at constant exchange rates (1).

In the second quarter of 2014, Sanofi sales were €8,075 million, an increase of 0.9% on a reported basis. Exchange rate movements had a negative effect of 5.5 percentage points primarily reflecting the strength of the euro versus other currencies, in particular the U.S. Dollar.

1 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,096.90 -106.47 -0.58%
S&P 500 2,098.53 -9.25 -0.44%
NASDAQ 4,967.1410 -12.76 -0.26%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs